Inactivation of human plasma C1-inhibitor by human PMN leucocyte matrix metalloproteinases  by Knäuper, Vera et al.
Volume 290, number 1,2, 99-102 FEES 10172 
0 1991 Federation of European Biochemical Societies 00145793/91/$3.50 
ADONIS 0014579391008846 
September 199 1 
Vera Ktiliuper, Susarme Triebel, Heinz Reinke and Harald Tschesche 
University of Biefefeld, Faculty of Chemistry. Department of Biochemistry. PO Box 8640, D-4800 Bielefeld I, Germany 
Received 18 July 1991 
Highly purified human polymorphonuclear (PMN) leucocyte matrix metalloproteinases, collagenase and gelatinase, cleaved human plasma 
Cl-inhibitor at the carboxyl site of Ala43u (P& This led to a concomitant loss of Cl-inhibitor activity. An additional cleavage sjte, at the carboxyl 
site of Seru4’ (PJ, was observed during PMN leucocyte gelatinase-induced inactivation, and .a minor fragment of the plasma Cl -inhibitor was 
generated. 
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1. INTRODUCTION 
Cl-inhibitor inactivates proteinases of the comple- 
ment (Cl r, Cls), fibrinolytic (plasmin), kinin-genera- 
tion (kallikrein) and coagulation (factor XIa, XIEa) sys- 
tem by the formation of equimolar stoichiometric om- 
plexes between inhibitor and target proteinase [1,2]. 
Like in other members of the serine proteinase inhibitor 
(serpin) superfamily, the reactive site of Cl-inhibitor is 
located in an exposed loop near the C-terminus of the 
molecule [3-51. Limited proteolysis of Cl-inhibitor by 
chymotrypsin-like proteinases results in N-terminal mo- 
dification of the molecule without change in inhibitor 
capacity [5--71. Grin proteinases which are not inhibited 
by Cl-inhibitor can cleave within the reactive site loop 
resulting in a loss of inhibitory activity [G,r(,S]. This 
process is accompanied by a conformational rearrange- 
ment and an increase in heat stability. The physiological 
role of Cl -inhibitor has been demonstrated by its invol- 
vement in type I and type II hereditary angiooedema 
[l&12]. It has recently been shown, that human PMN 
leucocytes are able to inactivate Cl-inhibitor by limited 
proteolysis [6]. This is due to proteolytic cleavage of 
PMN leucocyte lastase on the N- and C-terminal part 
of the inhibitor. Since the regulation of the complement 
system is critically dependent on a balance between C 1 r, 
Cls and their inhibitor, proteolytic inactivation of Cl- 
inhibitor by PMN leucocytes may result in complement 
activation. The influence of PMN leucocyte metallopro- 
teinases on the inhibitory activity of Cl-inhibitor is de- 
scribed in this report. The inactivation of Cl-inh.ibitor 
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by PMN leucocyte collagenase and gelatinase isdemon- 
strated, and we discuss tha possible role of PMN leuco- 
cyte metalloproteinases a antagonists of human plas- 
ma C I -inhibitor. 
2. MATERIALS AND METHODS 
2.1, Purification, activation and enzyme assay of PMN lertcocyte ma- 
trix metalloproteinases, collagenase and gelatinase 
PMN leucocyte procollagenase was purified to homogeneity exactly 
as recently published [13]. PMN leucocyte progelatinase was purified 
according to the method described by Wilhelm et al, for the homolo- 
gous enzyme from simian virus 40 transformed lung fibroblasts [ 141. 
It was demonstrated by N-terminal sequence determination that both 
enzyme preparations were homogeneous, showing the N-terminal se- 
quences of PMN leucocyte procollagenase and PMN leucocyte proge- 
latinase. Activation of both proenzymes was achieved by treatment 
with I mM HgClz for 2 h at 37°C. The enzymatic activity of PMN 
leucocyte collagenase and PMN leucocyte gelatinase was determined 
by the degradation of the synthesic octapeptide (DNp-Pro-Gln-Gly- 
Ile-Ala-Gly-Gln-DArg-OH) as described by Masui 1151. 
2.2, Proteolytic inactivation of Cl-inhibitor 
2 mg human Cl-inhibitor were incubated with 5 ,~g of either active 
PMN leucocyte collagcnase or PMN leucocyte gelatinase at 37°C for 
20 h. 
2.3. Purificatiopt of Cl-inhibitor degradation products by reverse-phase 
HPLC 
Fragments from the PMN leucocyte collagenase and PMN leuco- 
cyte gelatinase digests of Cl-inhibitor were separated by reverse-phase 
HPLC on a Bakerbond wide pore &-column (4.9 X 250 mm) at a 
constant flow rate of 0.8 ml/min using a linear gradient from O-80% 
acetonitrile. 
2.4. Sequence detern~ination 
N-terminal sequence determinations of the individual degradation 
products were performed by automated Edman degradation using a 
microsequencer (Model 810, Knauer, Berlin). Pth amino acids were 
separated on an Applied Biosystems Pth-C,,-column (220 x 2.1 mm) 
at a flow rate of 0.24 mllmin as recently published [16]. 
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Fig. 1. Cleavage of Cl-inhibitor by PMN leucocyte collagenase and 
gelatinase. 10% SDS-PAGE unreduced. The protein bands were 
stained with silver. Lane I, molecular mass markers; lane 2. I mg Cl- 
inhibitor incubated with buffee at 37°C for 24 h; lane 3, I mg Cl- 
inhibitor incubated with 5,q active collagenase at 37°C foe 24 h; lane 
4. 1 ma Cl-inhibitor incubated with 5 ug active collaaenase in the 
piesen& of EDTA; lane 5, 1 mg Cl-inhibitor incubated with 5 @g 
active gelatinase at 37°C for 24 h; lane 6.1 mg Cl-inhibitor incubated 
-with 5 pg active gelatinase in the preiencc of EDTA. 
Fig. 2. Reverse-phase HPLC of Cl-inhibitor and Cl-inhibitor degra- 
dation products (A) intact Cl-inhibitor: (E) active collagenase digest 
of Cl-inhibitor; 1, cleavage fragment Ilea N-terminus; (C) active 
gelatinase digest of Cl-inhibitor; I, cleavage fragment Ilea” N-termi- 
nus; 2, cleavage fragment ValU2 N-terminus. 
3. IWSIJLTS AND BISCWSSION 
The rapid proteolytis fragmentation of C 1 -inhibitor 
by highly purified PMN leucocyte collagenase and gela- 
2.5. SDS-PAGE 
The molecular masses of Cl-inhibitor and degradation products 
were analysed by SDS-PAGE as described by Laemmli [l7]. The 
proteins were stained with silver according to the protocol of Heu- 
keshoeven and Dernick [IX]. 
tinase was shown by SDS-PAGE (Fig. 1), reverse-phase 
I-IPLC (Fig. 2) and N-terminal sequence determination 
(Fig. 3). The native Cl-inhibitor was proteolytisally 
cleaved by PMN leucocyte collagenase and gelatinase 
at the Ala439-Ile440 peptide bond. This proteolytic clea- 
vage at the carboxyl site of Ala419 (P,), five residues pre- 
(N&) $.+p-N*. .l"&S-L-Q- “33F-V-E-P-I-L-E-V-6-S”” “4~~S-~-I-S-~-A~~*-T-L_L-V-F~E’- .476p,R-A478(C,,0,.,) 
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Fig. 3, Proteolytic modification of human Cl-inhibitor by various proteolytic enzymes as indicated by arrows. 
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Fig. 4. Demonstration of the toss of inhibitory capacity ofCl-inhibitor 
after proteotysis by PMN teucocyte coltagenase and getatinase. (a), 
inactivation of Cl-inhibitor by collagenase after 24 h at 37°C; (A). 
inactivation of Cl-inhibitor by gelatinase after 24 h at 37°C; (0), intact 
Cl-inhibitor after 24 h incubation at 37°C in the presence of buffer. 
The inhibition of human plasmin (IO j&) by Cl-inhibitor (I mg/mt) 
is shown. 
ceding the reactive site, led to the concomitant inactiva- 
tion of the inhibitor (Fig. 4). A further minor fragment 
was generated by proteolytic cleavage of the Ser4”- 
Va1442 peptide bond by PMN leucocyte gelatinase within 
the protein core of the Cl-inhibitor. Inactivation of 
Cl-inhibitor by PMN leucocyte collagenase and gela.ti- 
nase was inhibited by EDTA or l,lO-phenanthroline 
(not shown) indicating metalloproteinase specific clea- 
vage. 
The fragmentation of C l-inhibitor by different prote- 
olytic enzymes of bacterial [9], reptilian [6] and human 
origin [6-81 has been investigated over the last ten years. 
The N-terminal and C-terminal region of the inhibitor 
is sensitive to proteolytic attack. I-Iowever, the loss of 
inhibitory activity is only observed when cleavages 
occur within the reactive site region of the molecule, 
which is located at the C-terminus [S]. This is followed 
by a significant conformational change in the exposed 
reactive site loop of the native inhibitor, which has been 
demonstrated by crystallisation of the inactivated ho- 
mologous serpin @,-PI [19]. Recently, Huber and 
Carrel1 [20] showed that the structural model of q-PI 
can generally act as a template for other members of the 
serpin family. 
Inactivation of Cl-inhibitor by proteinases derived 
from potentially pathogenic organisms or by human 
PMN leucocyte elastase would lead to an imbalance of 
the complement system. This would potentiate patholo- 
gical proteolysis at sites of inflammatory reactions. As 
it was recently shown that PMN leucocyte collagenase 
and g2latinase are regular plasma components [21], we 
investigated the ability of these matrix metalloproteina- 
ses to digest plasma components [22]. Both PMN leuco- 
cyte matrix metalloproteinases, collagenase and gelati- 
nase, can catalytically cleave Cl-inhibitor within the 
reactive site loop and thus may contribute to comple- 
ment activation during inflammation. These enzymes 
could possibly play an important role in the turnover of 
C 1 -inhibitor, since they are easily secreted upon specific 
stimuli and are optimally active at physiological pPI 
[23,24]. PMN leucocyte metalloproteinases may behave 
as the main antagonists of q-PI [22] or Cl-inhibitor. 
Proteolysis of these inhibitors results in the potentiation 
of inflammatory processes, which are regulated by these 
members of the serpin family. IMowever, the physiologi- 
cal significance of Cl-inhibitor inactivation by PMN 
leucocyte matrix metalloproteinases has yet to be deter- 
mined. 
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